-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28

Benzinga·10/28/2026 13:55:26
Listen to the news
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.